Trial Profile
Multicenter, Open-label, Phase II Safety and Efficacy Study of All-oral Combination Narlaprevir/Ritonavir and Daclatasvir Administered for 12 Weeks in Patients With Genotype 1b Chronic Hepatitis C
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 04 Nov 2021
Price :
$35
*
At a glance
- Drugs Daclatasvir (Primary) ; Narlaprevir (Primary) ; Ritonavir (Primary)
- Indications Hepatitis C
- Focus Therapeutic Use
- Sponsors R-Pharm
- 18 Dec 2018 Status changed from active, no longer recruiting to completed.
- 04 Apr 2018 New trial record